NCT04211740View on ClinicalTrials.gov

Phase II Clinical Trial of OCH-NCNP1

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Interventions
DRUG

OCH-NCNP1

OCH-NCNP1 3mg is supplied as granules and take orally once a week.

DRUG

Placebo

Placebo is supplied as granules and take orally once a week.

Trial Locations (1)

187-8551

National Center of Neurology and Psychiatry, Tokyo

All Listed Sponsors
lead

National Center of Neurology and Psychiatry, Japan

OTHER

NCT04211740 - Phase II Clinical Trial of OCH-NCNP1 | Biotech Hunter | Biotech Hunter